New study highlights the benefits of Kerry's branded ashwagandha for post-menopausal women

News
Article

A recent study investigated Sensoril Ashwagandha’s role in being a potential tool for post-menopausal women and aiding in the improvement of their quality of life.

Image | adobe.stock/fizkes

Image | adobe.stock/fizkes

The Kerry Group announced in a recent press release the results of a new clinical study demonstrating the potential benefits of its Sensoril Ashwagandha on the quality of life of post-menopausal women. In the study researchers found that 250 mg/day of Sensoril ashwagandha assisted post-menopausal women with their quality of life as well as management of their symptoms.

As women enter menopause, they may experience symptoms such as sleep disturbances, hot flashes, and mood swings. Researchers sought to “investigate the effects of dietary supplementation with standardized aqueous extracts of shatavari (Asparagus racemosus, Ar), ashwagandha (Withania somnifera, Ws), or their combination on menopausal symptoms, vascular dysfunction, bone turnover, and serum concentrations of inflammatory and oxidative stress markers in postmenopausal women.”1

To gather data, the study assigned 127 women between the ages of 40 to 55 years old to one of six groups via computer-generated block randomization. These groups were “1) placebo, 2) Ws 250 mg, 3) Ws 500 mg, 4) Ar 250 mg, 5) Ar 500 mg, and 6) Ws 250 mg + Ar 250 mg.”1 The participants were analyzed over a 24 week period and during that time had blood samples collected. Four participants dropped out before the first follow-up appointment. The study showed that women who received ashwagandha, experienced a decrease in their menopausal symptoms, bone turnover/resorption, vascular dysfunction, and estrogen deficiency-related inflammation and oxidative stress witnessed in postmenopausal women.

“Women are looking for a proactive approach to wellbeing, where their specific health needs are understood and met with the right product at the right time, and Kerry is rising to the occasion,” said Monica Maria Olivares, PhD, R&D director of women’s & infant health at Kerry, in the press release. “This study further supports the current and extensive research naming Sensoril a safe and effective solution. Driving progress in women’s health is of vital importance to us at Kerry, which is why we have curated a suite of naturally sourced and clinically studied ingredients that support women across every life stage.”

The study mentioned that participants taking the ashwagandha extract experienced:

  • 24% decrease in presence and severity of vasomotor symptoms
  • 16% decrease in presence and severity of psychosocial symptoms
  • 14% decrease in presence and severity of physical symptoms that were connected to sleep, aches and pains, strength, stamina, fatigue, energy, appearance
  • 13% decrease in presence and severity of issues related to sexual health

Additionally, the Kerry Group launched an online resource called “HerWay” which will help provide women with health and wellness issues and recent news on the latest market trends occurring in women’s health.

Reference

  1. Pingali U, Nutalapati C, Wang Y. Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study. J Menopausal Med. 2025 Mar;31:e2. https://doi.org/10.6118/jmm.24025
Related Content
© 2025 MJH Life Sciences

All rights reserved.